Cargando…

Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era

In recent years, the opioid epidemic and new hepatitis C virus (HCV) treatments have changed the landscape of organ procurement and allocation. We studied national trends in solid organ transplantation (2000–2016), focusing on graft utilization from HCV seropositive deceased donors in the pre-2014 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Andrew A., Cholankeril, George, Cheng, Xingxing S., Tan, Jane C., Kim, Donghee, Toll, Alice E., Nair, Satheesh, Ahmed, Aijaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165210/
https://www.ncbi.nlm.nih.gov/pubmed/29996536
http://dx.doi.org/10.3390/diseases6030062
_version_ 1783359783252787200
author Li, Andrew A.
Cholankeril, George
Cheng, Xingxing S.
Tan, Jane C.
Kim, Donghee
Toll, Alice E.
Nair, Satheesh
Ahmed, Aijaz
author_facet Li, Andrew A.
Cholankeril, George
Cheng, Xingxing S.
Tan, Jane C.
Kim, Donghee
Toll, Alice E.
Nair, Satheesh
Ahmed, Aijaz
author_sort Li, Andrew A.
collection PubMed
description In recent years, the opioid epidemic and new hepatitis C virus (HCV) treatments have changed the landscape of organ procurement and allocation. We studied national trends in solid organ transplantation (2000–2016), focusing on graft utilization from HCV seropositive deceased donors in the pre-2014 (2000–2013) versus current (2014–2016) eras with a retrospective analysis of the United Network for Organ Sharing database. During the study period, HCV seropositive donors increased from 181 to 661 donors/year. The rate of HCV seropositive donor transplants doubled from 2014 to 2016. Heart and lung transplantation data were too few to analyze. A higher number of HCV seropositive livers were transplanted into HCV seropositive recipients during the current era: 374 versus 124 liver transplants/year. Utilization rates for liver transplantation reached parity between HCV seropositive and non-HCV donors. While the number of HCV seropositive kidneys transplanted to HCV seropositive recipients increased from 165.4 to 334.7 kidneys/year from the pre-2014 era to the current era, utilization rates for kidneys remained lower in HCV seropositive than in non-HCV donors. In conclusion, relative underutilization of kidneys from HCV seropositive versus non-HCV donors has persisted, in contrast to trends in liver transplantation.
format Online
Article
Text
id pubmed-6165210
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61652102018-10-11 Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era Li, Andrew A. Cholankeril, George Cheng, Xingxing S. Tan, Jane C. Kim, Donghee Toll, Alice E. Nair, Satheesh Ahmed, Aijaz Diseases Article In recent years, the opioid epidemic and new hepatitis C virus (HCV) treatments have changed the landscape of organ procurement and allocation. We studied national trends in solid organ transplantation (2000–2016), focusing on graft utilization from HCV seropositive deceased donors in the pre-2014 (2000–2013) versus current (2014–2016) eras with a retrospective analysis of the United Network for Organ Sharing database. During the study period, HCV seropositive donors increased from 181 to 661 donors/year. The rate of HCV seropositive donor transplants doubled from 2014 to 2016. Heart and lung transplantation data were too few to analyze. A higher number of HCV seropositive livers were transplanted into HCV seropositive recipients during the current era: 374 versus 124 liver transplants/year. Utilization rates for liver transplantation reached parity between HCV seropositive and non-HCV donors. While the number of HCV seropositive kidneys transplanted to HCV seropositive recipients increased from 165.4 to 334.7 kidneys/year from the pre-2014 era to the current era, utilization rates for kidneys remained lower in HCV seropositive than in non-HCV donors. In conclusion, relative underutilization of kidneys from HCV seropositive versus non-HCV donors has persisted, in contrast to trends in liver transplantation. MDPI 2018-07-10 /pmc/articles/PMC6165210/ /pubmed/29996536 http://dx.doi.org/10.3390/diseases6030062 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Andrew A.
Cholankeril, George
Cheng, Xingxing S.
Tan, Jane C.
Kim, Donghee
Toll, Alice E.
Nair, Satheesh
Ahmed, Aijaz
Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era
title Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era
title_full Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era
title_fullStr Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era
title_full_unstemmed Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era
title_short Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era
title_sort underutilization of hepatitis c virus seropositive donor kidneys in the united states in the current opioid epidemic and direct-acting antiviral era
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165210/
https://www.ncbi.nlm.nih.gov/pubmed/29996536
http://dx.doi.org/10.3390/diseases6030062
work_keys_str_mv AT liandrewa underutilizationofhepatitiscvirusseropositivedonorkidneysintheunitedstatesinthecurrentopioidepidemicanddirectactingantiviralera
AT cholankerilgeorge underutilizationofhepatitiscvirusseropositivedonorkidneysintheunitedstatesinthecurrentopioidepidemicanddirectactingantiviralera
AT chengxingxings underutilizationofhepatitiscvirusseropositivedonorkidneysintheunitedstatesinthecurrentopioidepidemicanddirectactingantiviralera
AT tanjanec underutilizationofhepatitiscvirusseropositivedonorkidneysintheunitedstatesinthecurrentopioidepidemicanddirectactingantiviralera
AT kimdonghee underutilizationofhepatitiscvirusseropositivedonorkidneysintheunitedstatesinthecurrentopioidepidemicanddirectactingantiviralera
AT tollalicee underutilizationofhepatitiscvirusseropositivedonorkidneysintheunitedstatesinthecurrentopioidepidemicanddirectactingantiviralera
AT nairsatheesh underutilizationofhepatitiscvirusseropositivedonorkidneysintheunitedstatesinthecurrentopioidepidemicanddirectactingantiviralera
AT ahmedaijaz underutilizationofhepatitiscvirusseropositivedonorkidneysintheunitedstatesinthecurrentopioidepidemicanddirectactingantiviralera